Canine Arthritis Treatment

Global Canine Arthritis Treatment Market to Reach US$3.0 Billion by 2030

The global market for Canine Arthritis Treatment estimated at US$2.4 Billion in the year 2024, is expected to reach US$3.0 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. Drugs Treatment, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Supplements Treatment segment is estimated at 3.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$661.0 Million While China is Forecast to Grow at 6.7% CAGR

The Canine Arthritis Treatment market in the U.S. is estimated at US$661.0 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$600.4 Million by the year 2030 trailing a CAGR of 6.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Canine Arthritis Treatment Market - Key Trends & Drivers Summarized

Why Is Canine Arthritis a Growing Concern Among Pet Owners?

Canine arthritis has become a major health concern, particularly as advances in veterinary care lead to longer lifespans for dogs. This degenerative joint disease affects millions of pets globally, causing pain, reduced mobility, and a decline in quality of life. The increasing awareness among pet owners about joint health, combined with the rise in pet humanization trends, has significantly expanded the market for arthritis treatments. Veterinarians are now focusing on early diagnosis and multimodal treatment approaches to improve outcomes, driving demand for both pharmaceutical and non-pharmaceutical solutions. Additionally, the growing prevalence of obesity in dogs has exacerbated arthritis cases, further fueling the need for effective treatment options.

How Are Innovations in Veterinary Medicine Improving Arthritis Management?

The canine arthritis treatment market has seen significant advancements in recent years, with novel therapies offering improved pain relief and joint support. Regenerative medicine, including stem cell therapy and platelet-rich plasma (PRP) treatments, is gaining traction for its potential to repair damaged cartilage and slow disease progression. Advances in biologic drugs, such as monoclonal antibodies targeting pain pathways, have also revolutionized arthritis management, providing longer-lasting relief with fewer side effects. Additionally, the development of nutraceuticals, including omega-3 fatty acids and glucosamine supplements, has expanded non-invasive treatment options. Technological innovations in orthopedic braces and hydrotherapy equipment further support holistic arthritis care for aging dogs.

Which Market Segments Are Driving Demand for Canine Arthritis Treatments?

The demand for canine arthritis treatments is growing across multiple segments, including pet pharmaceuticals, veterinary clinics, pet insurance providers, and online pet health retailers. The pharmaceutical segment, encompassing NSAIDs, analgesics, and regenerative medicines, remains the largest contributor to market revenue. Veterinary clinics are increasingly offering specialized arthritis management programs, incorporating physiotherapy and lifestyle modifications. Pet insurance companies are playing a key role in market growth by covering advanced arthritis treatments, making them more accessible to pet owners. Additionally, direct-to-consumer pet health brands are expanding the availability of joint supplements and therapeutic diets through e-commerce channels.

What Factors Are Driving the Growth of the Canine Arthritis Treatment Market?

The growth in the canine arthritis treatment market is driven by several factors, including increasing pet longevity, rising awareness of joint health, and advancements in veterinary therapeutics. The shift toward preventive pet care and early intervention strategies has boosted demand for diagnostic tools and long-term arthritis management plans. The expanding pet insurance industry has also facilitated greater access to expensive treatment options, making advanced arthritis therapies more affordable. Additionally, the rise of online veterinary pharmacies and telemedicine services has improved accessibility to arthritis treatments, allowing pet owners to explore multiple care options. As pet owners continue to prioritize quality of life for their aging dogs, the demand for innovative and effective arthritis treatments is expected to rise.

SCOPE OF STUDY:

The report analyzes the Canine Arthritis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Treatment Type (Drugs Treatment, Supplements Treatment, Surgical Procedures, Other Treatment Types); Arthritis Type (Osteoarthritis Treatment, Osteochondrosis Treatment, Rheumatoid Arthritis Treatment, Traumatic Arthritis Treatment)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Adequan Canine (American Regent Animal Health)
• American Regent, Inc.
• Boehringer Ingelheim Animal Health
• Cartrophen Vet (Arthropharm)
• Cosequin (Nutramax Laboratories)
• Dasuquin (Nutramax Laboratories)
• Elanco Animal Health
• Liquid Health, Inc.
• Matsun Nutrition
• Nutramax Laboratories Veterinary Sciences, Inc.
• Nutri-Vet, LLC
• Parnell Pharmaceuticals Holdings Ltd.
• Pet Tech Labs
• Synflex America Inc.
• Thorne Research Inc.
• Vetalogica
• VetIQ
• Wuffes
• YuMOVE (Lintbells)
• Zoetis Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.